investor.foamix.co.il

Foamix | Investor Relations | Investor Relations Home

Foamix - Innovative, Versatile Topical Foams with IP protection. Foamix Pharmaceuticals Second Quarter 2015 Conference Call and Webcast Scheduled for Thursday, August 20. Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea. Foamix Receives Milestone Payment From Merz North America. Foamix to Present Corporate Overview at the Jefferies 2015 Global Healthcare Conference. 08/20/15 8:00 am ET.

http://investor.foamix.co.il/

OVERVIEW OF investor.foamix.co.il

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

0

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.FOAMIX.CO.IL

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

June

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.4 out of 5 with 5 reviews

5 star

2

4 star

3

3 star

0

2 star

0

1 star

0

Hey there! Start your review of investor.foamix.co.il

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

1.7 seconds

CONTACTS AT INVESTOR.FOAMIX.CO.IL

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

0

SSL

EXTERNAL LINKS

9

SITE IP

128.177.96.16

LOAD TIME

1.656 sec

SCORE

6.2

PAGE TITLE

Foamix | Investor Relations | Investor Relations Home | investor.foamix.co.il Reviews

<META> DESCRIPTION

Foamix - Innovative, Versatile Topical Foams with IP protection. Foamix Pharmaceuticals Second Quarter 2015 Conference Call and Webcast Scheduled for Thursday, August 20. Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea. Foamix Receives Milestone Payment From Merz North America. Foamix to Present Corporate Overview at the Jefferies 2015 Global Healthcare Conference. 08/20/15 8:00 am ET.

<META> KEYWORDS

1 formulation

2 dermatology

3 tamarkin

4 dov tamarkin

5 meir eini

6 transdermal

7 transdermal drug

8 transdermal drug delivery

9 dermatology foam

10 topical

CONTENT

Page content here

KEYWORDS ON PAGE

technology,lead products,early stage products,partnering,intellectual property,press room,investors,investor relations home,stock information,corporate profile,recent news,date,title,upcoming events,receive e mail alerts,company overview,investor calendar

CONTENT-TYPE

windows-1255

GOOGLE PREVIEW

Foamix | Investor Relations | Investor Relations Home | investor.foamix.co.il Reviews

https://investor.foamix.co.il

Foamix - Innovative, Versatile Topical Foams with IP protection. Foamix Pharmaceuticals Second Quarter 2015 Conference Call and Webcast Scheduled for Thursday, August 20. Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea. Foamix Receives Milestone Payment From Merz North America. Foamix to Present Corporate Overview at the Jefferies 2015 Global Healthcare Conference. 08/20/15 8:00 am ET.

LINKS TO THIS WEBSITE

foamix.co.il

FMX101 for Moderate-to-Severe Acne

http://foamix.co.il/lead.asp

Foamix - Innovative, Versatile Topical Foams with IP protection. FMX101 for Moderate-to-Severe Acne. Foamix is developing FMX101, a 4% minocycline foam product candidate for the treatment of moderate-to-severe acne. Oral antibiotics, such as minocycline and doxycycline, are the most commonly used treatments for moderate-to-severe cases of acne. In 2009, the FDA added oral minocycline to its Adverse Event Reporting System, a list of medications under investigation by the FDA for their severe side effects.

foamix.co.il

Mometasone Foam

http://foamix.co.il/products.asp

Foamix - Innovative, Versatile Topical Foams with IP protection. Mometasone Furoate 0.1%. Clinical stage - Phase I/II. Psoriasis, atopic dermatitis and other steroid-responsive dermatoses. Foam formulations offer good spreadability and facile absorption; extensive rubbing onto the skin is not necessary. The superior usability profile of foam is particularly valuable in the treatment of psoriasis and atopic dermatitis, which involves application to large and sensitive skin surfaces. About 6.4 million ...

foamix.co.il

Intellectual Property

http://foamix.co.il/ip.asp

Foamix - Innovative, Versatile Topical Foams with IP protection. The protection of our proprietary technology and products through patents and other enforceable intellectual property rights that we own or license is a key to our business and competitive position. As of January 1, 2016, Foamix has over 138 issued patents worldwide, including 45 in the United States, together with over 100 pending patent applications worldwide.

foamix.co.il

Partnering

http://foamix.co.il/partnering.asp

Foamix - Innovative, Versatile Topical Foams with IP protection. Taking drugs from API to fully developed foam: Formulation under Foamix’s intellectual property. Foamix is working with leading pharmaceutical companies from around the world, to develop unique products with a strong competitive edge. What can you expect when working with Foamix? Foamix development process - taking you from A to Z. Analytical methods - development and validation:. One of the most important objectives in the development of t...

foamix.co.il

FMX101 for Moderate-to-Severe Acne

http://foamix.co.il/lead.asp?nodeID=549

Foamix - Innovative, Versatile Topical Foams with IP protection. FMX101 for Moderate-to-Severe Acne. Foamix is developing FMX101, a 4% minocycline foam product candidate for the treatment of moderate-to-severe acne. Oral antibiotics, such as minocycline and doxycycline, are the most commonly used treatments for moderate-to-severe cases of acne. In 2009, the FDA added oral minocycline to its Adverse Event Reporting System, a list of medications under investigation by the FDA for their severe side effects.

foamix.co.il

Company Profile

http://foamix.co.il/about.asp

Foamix - Innovative, Versatile Topical Foams with IP protection. In addition, the company has development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.

foamix.co.il

Press Releases

http://foamix.co.il/ir.asp

Foamix - Innovative, Versatile Topical Foams with IP protection. Foamix Reports Second Quarter 2016 Financial Results and Provides Business Update. Foamix Pharmaceuticals Second Quarter Financial Results Conference Call and Webcast Scheduled for Wednesday, August 10. Foamix to Present at the BIO International Convention. Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting. Foamix Announces Positive Results from Phase I.

foamix.co.il

Press Releases

http://foamix.co.il/news.asp?nodeID=564&itemID=112

Foamix - Innovative, Versatile Topical Foams with IP protection. Foamix Reports Second Quarter 2016 Financial Results and Provides Business Update. Foamix Pharmaceuticals Second Quarter Financial Results Conference Call and Webcast Scheduled for Wednesday, August 10. Foamix to Present at the BIO International Convention. Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting. Foamix Announces Positive Results from Phase I.

foamix.co.il

Press Releases

http://foamix.co.il/news.asp?nodeID=564&itemID=114

Foamix - Innovative, Versatile Topical Foams with IP protection. Foamix Reports Second Quarter 2016 Financial Results and Provides Business Update. Foamix Pharmaceuticals Second Quarter Financial Results Conference Call and Webcast Scheduled for Wednesday, August 10. Foamix to Present at the BIO International Convention. Foamix Pharmaceuticals Announces Publication of Abstract on FDX-104 in the Treatment of EGFRI Induced Rash for the 2016 ASCO Meeting. Foamix Announces Positive Results from Phase I.

UPGRADE TO PREMIUM TO VIEW 0 MORE

TOTAL LINKS TO THIS WEBSITE

9

OTHER SITES

investor.fleetcor.com

FLEETCOR - Investor Relations

News and Press Archive. A Leader in Global Business Solutions. Specialty Payment and Other Services. We believe that business works best when everyone involved is informed and empowered. We are dedicated to making sure that you are always aware of our investments, achievements and strategies. View FLEETCOR’s quarterly results, SEC reports, annual reports and other financial information. Find the answers to your most frequently asked questions and get a closer look at our investors. 16000 . 160; 0.99.

investor.flir.com

FLIR Investor Relations

Chemical and Biological Agents. Firefighting and Fire Service. Test and Measurement Meters. Shortwave IR (SWIR) and Low Light Camera Cores. ROICs and Imaging Components. Pan / Tilt Systems. Commercial Vision Systems Sales Offices. Government Systems Sales Offices. Investor Presentation - July 2015. Archived Events and Presentations. Jul 24, 2015. FLIR Systems Announces Second Quarter 2015 Financial Results. Jul 9, 2015. FLIR Systems to Release Second Quarter 2015 Financial Results on Friday, July 24, 2015.

investor.fluor.com

Fluor Corporation - Investor Relations - Investor Relations

Community & Social Service. Gas Processing and LNG. Gasification, Gas to Liquids, and IGCC. Heavy Oil Upgrading and Oil Sands. Hydrocarbon Transportation - Pipelines. Offshore Oil and Gas Production. Onshore Oil and Gas Production. Plant Engineering and Construction. Equipment, Tools and Fleet Services. Construction HSE (Health Safety and Environment). Compliance and Ethics Program. Compliance and Ethics in Action. Compliance and Ethics Hotline. Diversity and Inclusion Commitment. Annual Report and Proxy.

investor.fnf.com

Fidelity National Financial, Inc. - Investor Relations

Fidelity National Financial, Inc. View all ». Mar 19, 2018. Fidelity National Financial, Inc. Announces Signing of a Merger Agreement to Acquire Stewart Information Services for $50 per Share in Combination of Cash and FNF Common Stock. Jan 30, 2018. Fidelity National Financial, Inc. Announces 11% Increase in Quarterly Cash Dividend to $0.30. Tax Basis Information for Black Knight Distribution to FNF Shareholders. Tax Basis Information for J. Alexander's Stock Distribution to FNFV Shareholders.

investor.fntg.com

Fidelity National Financial, Inc. - Investor Relations

Fidelity National Financial, Inc. View all ». Mar 19, 2018. Fidelity National Financial, Inc. Announces Signing of a Merger Agreement to Acquire Stewart Information Services for $50 per Share in Combination of Cash and FNF Common Stock. Jan 30, 2018. Fidelity National Financial, Inc. Announces 11% Increase in Quarterly Cash Dividend to $0.30. Tax Basis Information for Black Knight Distribution to FNF Shareholders. Tax Basis Information for J. Alexander's Stock Distribution to FNFV Shareholders.

investor.foamix.co.il

Foamix | Investor Relations | Investor Relations Home

Foamix - Innovative, Versatile Topical Foams with IP protection. Foamix Pharmaceuticals Second Quarter 2015 Conference Call and Webcast Scheduled for Thursday, August 20. Finacea(R) (azelaic acid) Foam 15%, Approved by U.S. FDA for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea. Foamix Receives Milestone Payment From Merz North America. Foamix to Present Corporate Overview at the Jefferies 2015 Global Healthcare Conference. 08/20/15 8:00 am ET.

investor.fontan.od.ua

Сайт investor.fontan.od.ua не настроен на сервере

Сайт investor.fontan.od.ua не настроен на сервере. Сайт investor.fontan.od.ua. Не настроен на сервере хостинга. Адресная запись домена ссылается на наш сервер, но этот сайт не обслуживается. Если Вы недавно добавили сайт в панель управления - подождите 15 минут и ваш сайт начнет работать.

investor.foresight.com

Foresight Energy / Investor Relations / Investor Relations

News and Market Information. Information / 10-K Request. Foresight Energy LP Second Quarter 2015 Earnings Call. Thursday, July 30, 2015. Foresight Energy LP (NYSE: FELP). Foresight Energy Temporarily Idles Longwall Mining Operations At Deer Run Mine. Foresight Energy LP Announces Second Quarter 2015 Results. Foresight Energy Resumes Longwall Mining Operations At Deer Run Mine And Will Conduct Longwall Move. As of August 14, 2015. Minimum 20 minute delay. 211 North Broadway, Suite 2600. St Louis, MO 63102.

investor.forestargroup.com

Investor Relations | Forestar

Find Land for Sale. Find a Mineral Lease. Financial and SEC Reporting. Forestar (FOR) Stock Quote. 160; 0.2. Data as of 08/07/15 4:00 PM ET. Minimum 20 Minute Delay. Powered by EDGAR Online. Welcome to Investor Relations. Forestar is a real estate and natural resources company with a strategy to recognize and responsibly deliver the greatest value from every acre. Wednesday, August 5, 2015 9:00AM CT. Webcast: Q2/15 Results Conference Call and Materials. Forestar's 2014 Annual Report. Acquiring, Entitling...

investor.fortinet.com

Investor Relations - Fortinet, Inc.

Cloud Access Security Broker. Identity and Access Management. Small and Midsize Business Categories. Enterprise and Midsize Business. Latest Advisories and Threat Responses. Visit FortiGuard Labs Center. New Threat Landscape Report. FortiGuard Threat Intelligence Service. Sign up as a Customer. Enterprise and Midsize Business. Communications Service Provider Security. Managed Security Service Provider. SCADA / Industrial Control. Advanced Services for Enterprise. Advanced Services for Service Providers.

investor.fplgroup.com

NextEra Energy, Inc. | Investor Relations | Investor Relations Home | Wind Energy Stocks, Solar Energy Stocks, FPL Stock

Analyst Estimates and Ratings. Dividend Reinvestment and Direct Stock Purchase. Sustaining superior growth through superior operational performance. NextEra Energy and NextEra Energy Partners to participate in the Goldman Sachs Power, Utilities, MLP and Pipeline Conference. NextEra Energy reports 2015 second-quarter financial results. NextEra Energy Capital Holdings announces dates for remarketing of its Series F Debentures due Sept. 1, 2017. View More Financial News. Europe 2015 Investor Presentation.